SureTrader Nadex Advertisement
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

BPTH RSS Feed
Add BPTH Price Alert      Hide Sticky   Hide Intro
Moderator: SJSTOCKSHARK
Search This Board: 
Last Post: 2/23/2017 4:44:43 PM - Followers: 37 - Board type: Free - Posts Today: 0

Bio-path Holdings Inc.

Company Description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001 has completed a combination (with LDAC) safety phase  8 cohort for treatment of AML. No toxicity was seen. 5 out of 6 patients acheived at least partial remission. 50% had total remission! The company has completed the review by the FDA for this drug to begin phase II. The patient dosing has begun at trials which will occur at up to 8 sites or more, including MD Anderson, Baylor and University of Kansas.


Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug is BP1001 targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the 8 cohort of phase 1 (treating different types of leukemia) there has been absolutely no toxicity. Testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating our delivery system. With the completion of the combination safety trials with LDAC and FDA approval, phase 2 has begun and is accepting patients.  This trial will occur at several sites. The purpose of phase 2 will be to test the effectiveness of the drug. The company may explore FDA accelerated status after testing is complete on 19 additional patients which is expected to occur in mid 2017. A CML combination drug safety study for BP1001 is also expected to be completed by mid 2017.
 
Bio-Path Holdings will also begin phase 1 testing of their antisense drug BP1001 on certain types of breast cancer which the date have been resistant to treatment.  Additionally, BPTH is initiating development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected for early 2017.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.


http://www.biopathholdings.com


While antisense drugs fell out of favor following Gilead's failed efforts there is now renewed interest.  Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. If Bio-Path holdings proves the validity of their delivery system, I would expect similar partnerships.

This link to the company website describes their novel delivery technology:


http://biopathholdings.com/technology/


The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson was the largest shareholder. After raising an additional 10 million dollars the company has $11+ million in cash. These funds should allow the company to start phase II testing of their antisense drug BP1001 on leukemia and begin phase I testing for breast cancer. The company has an "at the market" credit facility in place with Cantor Fitzgerald to raise another $25 million.

 
Bio-Path Holdings do not manufacture their drug but uses contractors. Once the efficacy of BP1001 is established, I would anticipate a manufacturing partnership will occur. The CEO says the company has now ramped up their structure as they are a phase 2 developmental company.
 
BPTH is traded on the NASDAQ.

Here is the link to the recent peer paper prepared by their experts:

http://www.biopathholdings.com/pdf/PeerExpertOpinion20150107.pdf

Analyst target price: Maxim $2, Rodman & Renshaw $5

Zack's upgraded rating now equals 3 or hold.
                        
 
 
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BPTH
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#2465   I would say a Moon Shot individual should SJSTOCKSHARK 02/23/17 04:44:43 PM
#2464   SJ, you are correct, I mis-read the announcement. Snug9 02/23/17 03:06:39 AM
#2463   Snug, I understood Dr Hooper was on the SJSTOCKSHARK 02/22/17 09:53:53 PM
#2462   SJ, when I look at the appointment of Snug9 02/22/17 06:21:30 PM
#2461   Yep, I went back and listened, I sure too simple 02/22/17 03:24:53 PM
#2460   GP, PN said 10 sites by April. Cornell SJSTOCKSHARK 02/22/17 11:33:59 AM
#2459   SJ, the recent presentation by PN mentioned four Gpheart2016 02/22/17 11:28:51 AM
#2458   Dr. Hooper is a researcher not a business SJSTOCKSHARK 02/22/17 10:44:24 AM
#2457   How do you see what other boards he dmoffat 02/21/17 08:04:05 PM
#2456   SJS, I agree 100%. I wonder what they too simple 02/21/17 05:24:59 PM
#2455   In researching Dr. Hooper I see he has SJSTOCKSHARK 02/21/17 04:53:49 PM
#2454   GP, I also feel your frustration and I SJSTOCKSHARK 02/21/17 04:36:09 PM
#2452   WOW, I thought we might approach the 1.00 Gpheart2016 02/21/17 01:25:10 PM
#2451   Snug, When you combine the announcement today with SJSTOCKSHARK 02/21/17 11:49:44 AM
#2450   Dr. Hooper has a great pedigree for a Snug9 02/21/17 11:24:32 AM
#2449   HOUSTON, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Bio-Path SJSTOCKSHARK 02/21/17 11:09:31 AM
#2448   I have been out of touch for a Gpheart2016 02/20/17 10:13:53 AM
#2447   Perhaps this explains the barrier to the upward SJSTOCKSHARK 02/17/17 01:53:32 PM
#2446   GP. It looks like a concerted effort to SJSTOCKSHARK 02/17/17 11:09:42 AM
#2445   That would be brutal! They should have been dmoffat 02/17/17 06:55:38 AM
#2444   Inventor, That would be good news. I hope SJSTOCKSHARK 02/16/17 03:25:06 PM
#2443   I believe the institutional buying is increasing substantially inventor1 02/16/17 02:45:00 PM
#2442   Perhaps PN is afraid one these experienced investors SJSTOCKSHARK 02/15/17 09:37:34 PM
#2440   SJ, In my earlier post the major investor Snug9 02/15/17 02:05:22 PM
#2439   Wow! If PN is turning down help from Pat Torney 02/15/17 02:03:55 PM
#2438   Here come the 70s, time to get out iloveu2 02/14/17 06:13:13 PM
#2437   Wow, more of the same. Not really surprised. dmoffat 02/14/17 03:46:07 PM
#2436   Brettj, Welcome back. I agree PN is a SJSTOCKSHARK 02/14/17 01:04:19 PM
#2435   Wow, why does Peter still present. It was Brettj 02/14/17 11:25:11 AM
#2434   SJ, I sure hope I'm wrong about the Snug9 02/09/17 03:37:08 PM
#2433   SJS, I agree 100% with you and everything too simple 02/09/17 03:36:42 PM
#2432   Ilove, I hope you are incorrect. The volume SJSTOCKSHARK 02/09/17 12:59:11 PM
#2431   Unfortunately we may see the 70 cent range iloveu2 02/09/17 12:53:19 PM
#2430   Snug, I agree that the management has been SJSTOCKSHARK 02/09/17 12:43:59 PM
#2429   DMoffat I think this has been Peter's sinister Snug9 02/08/17 12:09:02 PM
#2428   If i had to bet .... he has vrock5656 02/08/17 10:07:48 AM
#2427   I am blown away by the fact that dmoffat 02/08/17 09:40:04 AM
#2426   It is no secret what my feelings about Snug9 02/08/17 02:54:14 AM
#2425   ONCE AGAIN FEELING SCAMMED ! vrock5656 02/07/17 04:55:22 PM
#2424   They say that, but last time people on Pat Torney 02/07/17 11:08:43 AM
#2423   Patents for the deliver system from BPTH'S website: SJSTOCKSHARK 02/06/17 07:39:22 PM
#2422   I think we discussed before, but I believe Pat Torney 02/06/17 02:13:19 PM
#2421   I've certainly enjoyed reading the posting here from BULLDOZER1 02/03/17 10:28:37 PM
#2420   The delivery system is important but monetizing it SJSTOCKSHARK 02/03/17 10:24:25 PM
#2419   Can someone help me understand something. When I too simple 02/03/17 02:12:22 PM
#2418   GP, Maybe this relates to the financing? Is SJSTOCKSHARK 02/03/17 01:26:44 PM
#2417   Looks like we are struggling to keep the Gpheart2016 02/03/17 11:28:49 AM
#2416   Thanks GP. SJSTOCKSHARK 02/02/17 05:43:43 PM
#2415   Looks like we found a support level in Gpheart2016 02/02/17 05:00:38 PM
#2414   It looks like most of that institutional buying dmoffat 02/02/17 02:22:02 PM
PostSubject